MX2020009552A - Composiciones para prevenir y/o tratar melanoma. - Google Patents
Composiciones para prevenir y/o tratar melanoma.Info
- Publication number
- MX2020009552A MX2020009552A MX2020009552A MX2020009552A MX2020009552A MX 2020009552 A MX2020009552 A MX 2020009552A MX 2020009552 A MX2020009552 A MX 2020009552A MX 2020009552 A MX2020009552 A MX 2020009552A MX 2020009552 A MX2020009552 A MX 2020009552A
- Authority
- MX
- Mexico
- Prior art keywords
- melanoma
- methods
- dapansutrile
- treating melanoma
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862645999P | 2018-03-21 | 2018-03-21 | |
| PCT/US2019/022770 WO2019182981A1 (en) | 2018-03-21 | 2019-03-18 | Methods for treating melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009552A true MX2020009552A (es) | 2020-10-05 |
Family
ID=67987925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009552A MX2020009552A (es) | 2018-03-21 | 2019-03-18 | Composiciones para prevenir y/o tratar melanoma. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11857529B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3768384B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7229565B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111867678B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3094307A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020009552A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019182981A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12121565B2 (en) * | 2019-09-13 | 2024-10-22 | Duke University | Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies |
| EP4045009A4 (en) * | 2019-10-14 | 2023-11-01 | Olatec Therapeutics LLC | METHOD FOR TREATING BREAST CANCER |
| EP4387729A4 (en) * | 2021-08-19 | 2025-07-09 | Olatec Therapeutics Inc | METHODS OF TREATMENT OF PARKINSON'S DISEASE |
| WO2026035767A1 (en) * | 2024-08-06 | 2026-02-12 | Olatec Therapeutics, Inc. | Methods for treating melanoma metastasis to liver and lungs |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013006708A (es) * | 2010-12-15 | 2013-09-13 | Olatec Ind Llc | Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor. |
| CA2875053C (en) * | 2012-06-05 | 2020-07-14 | Olatec Industries Llc | Pharmaceutical composition for treating inflammation and pain |
| JP6185575B2 (ja) * | 2012-06-05 | 2017-08-23 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 皮膚炎症性疾患の治療方法 |
| JP6929792B2 (ja) * | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| EP3288980B1 (en) * | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| EP3445761A1 (en) * | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| ES2970485T3 (es) * | 2017-01-06 | 2024-05-29 | Olatec Therapeutics Llc | Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares |
| EP3589370A4 (en) * | 2017-01-06 | 2020-11-18 | Olatec Therapeutics LLC | MULTIPLE SCLEROSIS TREATMENT METHOD |
| US20210254056A1 (en) | 2017-05-05 | 2021-08-19 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
| WO2019152627A1 (en) * | 2018-01-31 | 2019-08-08 | Olatec Therapeutics Llc | Method for preventing or treating alzheimer's disease |
-
2019
- 2019-03-18 JP JP2020550082A patent/JP7229565B2/ja active Active
- 2019-03-18 CN CN201980020523.3A patent/CN111867678B/zh active Active
- 2019-03-18 WO PCT/US2019/022770 patent/WO2019182981A1/en not_active Ceased
- 2019-03-18 CA CA3094307A patent/CA3094307A1/en active Pending
- 2019-03-18 EP EP19771591.5A patent/EP3768384B1/en active Active
- 2019-03-18 MX MX2020009552A patent/MX2020009552A/es unknown
-
2020
- 2020-09-15 US US17/021,733 patent/US11857529B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021518374A (ja) | 2021-08-02 |
| WO2019182981A1 (en) | 2019-09-26 |
| JP7229565B2 (ja) | 2023-02-28 |
| CN111867678A (zh) | 2020-10-30 |
| EP3768384A4 (en) | 2021-11-17 |
| EP3768384B1 (en) | 2025-06-25 |
| CA3094307A1 (en) | 2019-09-26 |
| US20200405681A1 (en) | 2020-12-31 |
| EP3768384A1 (en) | 2021-01-27 |
| US11857529B2 (en) | 2024-01-02 |
| CN111867678B (zh) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000054A (es) | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). | |
| AR126205A2 (es) | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario | |
| MX382902B (es) | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. | |
| CR20220545A (es) | ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) | |
| PH12020500576A1 (en) | Method of treating cancers with antagonistic anti-pd-1 antibodies | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| MX2018003824A (es) | Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control. | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2019014274A (es) | Metodo de tratamiento. | |
| MY201811A (en) | Method of reducing neutropenia | |
| PH12019502316A1 (en) | Combination cancer immunotheraphy with pentaaza macrocyclic ring complex | |
| MX2021012977A (es) | Tratamiento del cáncer con tg02. | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX386613B (es) | El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto. | |
| MX394355B (es) | Método de tratamiento de meduloblastoma con un inhibidor de ezh2. | |
| ZA202201713B (en) | Improved treatment using eyp001 | |
| EA201992431A1 (ru) | Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса | |
| JOP20210245A1 (ar) | طرق لعلاج الداء النشواني من النوع خفيف السلسلة | |
| MX2019010101A (es) | Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1. | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| EA201591424A1 (ru) | Способы лечения дефицита железа растворимым пирофосфатом железа | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| HK1252514A1 (zh) | 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use |